Form 4: Eledon Director Keith Katkin Converts RSUs to Common Stock

Eledon Pharmaceuticals Director Keith Katkin converted 8,575 restricted stock units into common stock on January 10, 2026.

Summary

• Keith Katkin, a Director of Eledon Pharmaceuticals, Inc., reported a change in beneficial ownership.
• On January 10, 2026, Katkin acquired 8,575 shares of Eledon Pharmaceuticals common stock.
• This acquisition resulted from the vesting and settlement of restricted stock units (RSUs).
• The RSUs were granted on January 10, 2025, and vested 100% on January 10, 2026.
• The transaction price for the acquisition was $0, as it represents the conversion of previously granted RSUs.
• Following this transaction, Katkin directly beneficially owns 8,575 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where a director converted restricted stock units into common stock, which is generally seen as a positive for aligning management interests with shareholders.

Positives

• Director Keith Katkin's acquisition of 8,575 shares of common stock increases his direct beneficial ownership, aligning his interests with shareholders.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This Form 4 filing details a company-specific insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to direct ownership.

Key Dates

Keywords

Eledon Pharmaceuticals, ELDN, Keith Katkin, Form 4, insider transaction, restricted stock units, RSU, common stock, director, beneficial ownership